GlassScriptPhysician profile
Darren R Blumberg
NPI 1902813272
$9,708.76
in general payments reported to CMS, 2019-2025
28 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $799 · 2021: $956 · 2022: $1,465 · 2023: $1,590 · 2024: $1,637 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,878 · Education: $46.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,878.10 |
| Education | $46.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,753.81 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,755.98 | 2019-2025 | Trulance, Relistor, Xifaxan |
| Pfizer INC. | $839.76 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $810.38 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $653.81 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $614.50 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $587.91 | 2019-2025 | Linzess |
| Ardelyx, INC. | $232.42 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $170.72 | 2019-2024 | Rebyota |
| Lilly USA, LLC | $165.54 | 2023-2025 | Omvoh |
| Allergan, INC. | $155.68 | 2019 | |
| Merck Sharp & Dohme LLC | $144.56 | 2019-2022 | |
| Evoke Pharma, INC. | $128.49 | 2022-2025 | Gimoti |
| Phathom Pharmaceuticals, INC. | $116.08 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $103.18 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $70.17 | 2023-2025 | Dupixent |
| Ucb, INC. | $55.14 | 2019-2020 | |
| Celltrion USA INC. | $46.44 | 2023-2024 | Zymfentra, Yuflyma |
| Nestle Healthcare Nutrition INC. | $44.99 | 2021 | |
| Braintree Laboratories, INC. | $41.11 | 2020-2024 | Suflave |
| Gilead Sciences, INC. | $37.70 | 2019-2021 | |
| Genzyme Corporation | $37.13 | 2023-2024 | |
| Qol Medical, LLC | $35.37 | 2021-2024 | Sucraid |
| Aimmune Therapeutics, INC. | $32.94 | 2025 | Zenpep |
| Redhill Biopharma INC. | $28.13 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.36 | 2025 | Iqirvo |
| Novo Nordisk INC | $16.25 | 2025 | Wegovy |
| Alfasigma USA, INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Blumberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.